• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Pregnancy - Pipeline Review, H2 2012 Product Image

Pregnancy - Pipeline Review, H2 2012

  • Published: September 2012
  • 32 pages
  • Global Markets Direct

Pregnancy – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Pregnancy - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Pregnancy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pregnancy. Pregnancy - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Pregnancy.
- A review of the Pregnancy products under development by companies and universities/research institutes based on information derived from company and READ MORE >

2
List of Tables 3
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Pregnancy Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Pregnancy 7
Pregnancy Therapeutics under Investigation by Universities/Institutes 9
Late Stage Products 10
Comparative Analysis 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Pregnancy Therapeutics – Products under Investigation by Universities/Institutes 12
Pregnancy – Therapeutics Assessment 13
Assessment by Monotherapy Products 13
Assessment by Route of Administration 14
Assessment by Molecule Type 16
Drug Profiles 18
pemetrexed disodium - Drug Profile 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
metformin - Drug Profile 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
17-Hydroxyprogesterone Caproate - Drug Profile 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
methotrexate - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
progesterone - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
progesterone - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
aspirin - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Pregnancy Therapeutics - Dormant Products 27
Pregnancy – Product Development Milestones 28
Featured News & Press Releases 28
Dec 21, 2011: VIVUS Reports Topline Findings From FORTRESS 28
Mar 30, 2011: Columbia's Provides Update On PREGNANT Study Publication 29
Feb 07, 2011: Pantec Biosolutions Reports First Successful IVF Pregnancy Using P.L.E.A.S.E. -FSH Patch 29
Nov 29, 2010: Ark Announces Positive Pre-Clinical Results For EG013 In Treatment Of Fetal Growth Restriction 29
Appendix 31
Methodology 31
Coverage 31
Secondary Research 31
Primary Research 31
Expert Panel Validation 31
Contact Us 32
Disclaimer 32

List of Tables
Number of Products Under Development for Pregnancy, H2 2012 7
Products under Development for Pregnancy – Comparative Analysis, H2 2012 8
Number of Products under Investigation by Universities/Institutes, H2 2012 9
Comparative Analysis by Late Stage Development, H2 2012 10
Comparative Analysis by Mid Clinical Stage Development, H2 2012 11
Products under Investigation by Universities/Institutes, H2 2012 12
Assessment by Monotherapy Products, H2 2012 13
Assessment by Stage and Route of Administration, H2 2012 15
Assessment by Stage and Molecule Type, H2 2012 17
Pregnancy Therapeutics – Dormant Products 27

List of Figures
Number of Products under Development for Pregnancy, H2 2012 7
Products under Development for Pregnancy – Comparative Analysis, H2 2012 8
Products under Investigation by Universities/Institutes, H2 2012 9
Late Stage Products, H2 2012 10
Mid Clinical Stage Products, H2 2012 11
Assessment by Monotherapy Products, H2 2012 13
Assessment by Route of Administration, H2 2012 14
Assessment by Stage and Route of Administration, H2 2012 15
Assessment by Molecule Type, H2 2012 16
Assessment by Stage and Molecule Type, H2 2012 17

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos